

# How to manage a patient with short QT syndrome?

Torino, 27 ottobre 2012

Carla Giustetto

Division of Cardiology  
University of Torino




# Short QT Syndrome

## A Familial Cause of Sudden Death


Fiorenzo Gaita, MD; Carla Giustetto, MD; Francesca Bianchi, MD; Christian Wolpert, MD;  
 Rainer Schimpf, MD; Riccardo Riccardi, MD; Stefano Grossi, MD;  
 Elena Richiardi, MD; Martin Borggrefe, MD

(*Circulation.* 2003;108:965-970.)




QT 280 ms QTc 260 ms

Narrow, tall and peaked T waves



High incidence of SD



QT 260 ms QTc 290 ms

Normal T waves

# Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG

Ramon Brugada, MD\*; Kui Hong, MD, PhD\*; Robert Dumaine, PhD; Jonathan Cordeiro, PhD; Fiorenzo Gaita, MD; Martin Borggrefe, MD; Teresa M. Menendez, MD; Josep Brugada, MD, PhD; Guido D. Pollevick, PhD; Christian Wolpert, MD; Elena Burashnikov, MS; Kiyotaka Matsuo, MD, PhD; Yue Sheng Wu, MD; Alejandra Guerchicoff, PhD; Francesca Bianchi, MD; Carla Giustetto, MD; Rainer Schimpf, MD; Pedro Brugada, MD, PhD; Charles Antzelevitch, PhD



*Circulation* 2004, 109:30-35

Two different mutations in KCNH2 (HERG) resulting in the same aminoacid change (N588K) in the S5-P loop region of the cardiac IKr channel



# Genetic Background


**SQT1**




**SQT2**



**SQT3**



**SQT4/5**








**SQT6**



SQT syndromes are due to enhanced K<sup>+</sup> current


Overlapping syndromes due to reduced Ca<sup>+</sup> currents



# Genotyped SQTS cases in the EuroShort registry

22 out of 72 patients

- KCNH2 - SQTS1
- KCNQ1 - SQTS2
- CACNB2b - SQTS5
- CACNA1D1 - SQTS6



In the EuroShort Registry genetic mutations were identified in **11 out of 28 (39%) probands** who performed the analysis

# Which is the upper limit of short QT ?

## Short QT syndrome: clinical findings and diagnostic–therapeutic implications

Carla Giustetto<sup>1\*</sup>, Fernando Di Monte<sup>1</sup>, Christian Wolpert<sup>2</sup>, Martin Borggrefe<sup>2</sup>, Rainer Schimpf<sup>2</sup>, Pascal Sbragia<sup>3</sup>, Gianpiero Leone<sup>4</sup>, Philippe Maury<sup>5</sup>, Olli Anttonen<sup>6</sup>, Michel Haissaguerre<sup>7</sup>, and Fiorenzo Gaita<sup>1</sup>

European Heart Journal (2006) 27, 2440–2447


$$QTc \leq 340 \text{ ms}$$

### CONTEMPORARY REVIEW

## The QT interval: Too long, too short or just right

Sami Viskin, MD

Heart Rhythm 2009;6:711–715






## Distribution of QTc intervals in large population-based studies.

12,000 adults (90% males)  
Gallagher, *Am J Cardiol* 2006.

11,000 adults (50% males)  
Funada, *Clin Cardiol* 2008.

40,000 conscripts (male)  
Kobza, *Heart Rhythm* 2009.



$$QTc \leq 360 \text{ ms}$$

# Long-Term Follow-Up of Patients With Short QT Syndrome

Carla Giustetto, MD,\* Rainer Schimpf, MD,† Andrea Mazzanti, MD,\* Chiara Scrocco, MD,\*  
Philippe Maury, MD,‡ Olli Anttonen, MD,§ Vincent Probst, MD, PhD,|| Jean-Jacques Blanc, MD,#  
Pascal Sbragia, MD,\*\* Paola Dalmaso, MS,†† Martin Borggrefe, MD,† Fiorenzo Gaita, MD\*


*J. Am. Coll. Cardiol.* 2011;58;587-595

**QTc ≤ 340 ms,  
even ASYMPTOMATIC**


**QTc ≤ 360 ms +  
cardiac arrest or syncope  
or belonging to families  
with SQTs**

# STRESS TEST - QT/HR relation

## SQTS 1 patients



## control group



rest QT - peak QT     $48.3 \pm 14.2$  ms     $106.7 \pm 20.8$  ms     $p < 0.0001$




# European Short QT Registry (Euro-Short)

**72 pts**

	(n = 72)
<b>Males</b>	<b>49 (74%)</b>
<b>Age at observation (y)</b>	<b>34 ± 17</b>
<b>Familial SD</b>	<b>47 (65%)</b>
<b>QT (ms)</b>	<b>285 ± 36</b>
<b>QTc (ms) [mean HR 76 ± 19]</b>	<b>315 ± 23</b>


## FIRST CLINICAL MANIFESTATION

- SD/Aborted SD
- Syncope
- Palpitations/AF
- Asymptomatic




# Reason of first clinical observation

42 index patients from European SQT Registry




# Age distribution of Cardiac Events in Males and Females



# THERAPY





**16 year- old boy with very short  
QT interval: QT 248 ms/  
QTc 252ms**


**Syncope at 6 months,  
then completely asymptomatic  
High incidence of sudden death  
in the family  
VF not induced during EPS**

**The dilemma was:  
what to do with this patient?**



# ICD interrogation may show episodes of rapid nsVT in asymptomatic subjects

M.Z., 58 year old



**ICD to everyone?**

**Early/Late  
complications**


**Children**



# Congenital Short QT Syndrome and Implantable Cardioverter Defibrillator Treatment: Inherent Risk for Inappropriate Shock Delivery


RAINER SCHIMPF, M.D., CHRISTIAN WOLPERT, M.D., FRANCESCA BIANCHI, M.D.,\*  
CARLA GIUSTETTO, M.D.,\* FIORENZO GAITA, M.D.,\* URS BAUERSFELD, M.D.,†  
and MARTIN BORGGREFE, M.D.

*J Cardiovasc Electrophysiol*, Vol. 14, pp. 1273-1277, December 2003



**T wave oversensing = double counting → Causing inappropriate shocks**

# Technical solutions to reduce T wave oversensing



Pts with Brugada Syndrome

**Late complications  
of ICD in pts with  
channelopathies**

	Pts with Brugada Syndrome		
	Sacher et al. Circ. 2006	Sarkozy et al. EHJ 2007	Rosso et al. IMAJ 2008
	220 pts f-up 38±27m	47 pts f-up 47.5m	59 pts f-up 45±35m
Lead failure requiring extraction and reimplantation of lead/device	<b>19 (8%)</b>	<b>6 (13%)</b>	<b>9 (15%)</b>
Pocket and/or lead infection requiring lead/device replacement	<b>3 (1.3%)</b>		<b>1 (2%)</b>
Pericardial effusion	<b>1 (0.5%)</b>		<b>1 (2%)</b>
Pocket revision	<b>2 (1%)</b>	<b>1 (2%)</b>	
Inappropriate shocks (due to: lead failure/dislodgement, T wave oversensing, sinus tachycardia, supraventricular arrhythmias)	<b>45 (20%)</b>	<b>19 (40%)</b>	<b>14 (24%)</b>
Severe psychological difficulties	<b>2 (1%)</b>		<b>8 (13%)</b>
<b>Total device related Complication</b>	<b>62 pts (28%)</b>	<b>18 pts (38%)</b>	<b>19 pts (32%)</b>

# ICD for everyone?



**Early/Late  
complications**

**Children**

# ICD implant in childhood

## Issues

**High technical complexity** due to:

small body and heart size

difficult vascular access

modifications of the implant owing to growth

**Psychosocial distress** linked to device discharges  
(**especially if inappropriate**)

High rates of **leads complications**

Pts with LQTS




**Late complications  
of ICD in children  
with LQTS**

	<b>Etheridge et al. JACC 2007</b>
	23 pts, mean age 9.4±5.4 y f-up 4.4 ± 3.5
Lead failure requiring extraction and reimplantation of lead/device	<b>2 (10%)</b>
Pocket and/or lead infection requiring lead/device replacement	<b>1 (4%)</b>
Pericardial effusion	
Pocket revision	
Inappropriate shocks (due to: lead failure/dislodgement, T wave oversensing, sinus tachycardia, supraventricular arrhythmias)	<b>4 (17%)</b>
Severe psychological difficulties	
<b>Total device related Complication</b>	<b>13 pts (48%)</b>

# THERAPY

**Drug therapy: may it play a role in the treatment of Short QT patients?**






# Short QT Syndrome: Pharmacological Treatment

Fiorenzo Gaita, MD; Carla Giustetto, MD; Francesca Bianchi, MD; Rainer Schimpf, MD; Michel Haissaguerre, MD; Leonardo Calò, MD; Ramon Brugada, MD; Charles Antzelevitch, PhD; Martin Borggrefe, MD; Christian Wolpert, MD.

J Am Coll Cardiol 2004; 43: 1494-99



**QUINIDINE**




# Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG

Ramon Brugada, MD\*; Kui Hong, MD, PhD\*; Robert Dumaine, PhD; Jonathan Cordeiro, PhD; Fiorenzo Gaita, MD; Martin Borggrefe, MD; Teresa M. Menendez, MD; Josep Brugada, MD, PhD; Guido D. Pollevick, PhD; Christian Wolpert, MD; Elena Burashnikov, MS; Kiyotaka Matsuo, MD, PhD; Yue Sheng Wu, MD; Alejandra Guerchicoff, PhD; Francesca Bianchi, MD; Carla Giustetto, MD; Rainer Schimpf, MD; Pedro Brugada, MD, PhD; Charles Antzelevitch, PhD



*Circulation* 2004, 109:30-35




**N588K mutation in HERG reduces the affinity of the  $I_{K_r}$  channel to **sotalolol** by **20-fold****

# Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG

CHRISTIAN WOLPERT, M.D., RAINER SCHIMPF, M.D., CARLA GIUSTETTO, M.D.,\*  
CHARLES ANTZELEVITCH, Ph.D.,† JONATHAN CORDEIRO, Ph.D.,†  
ROBERT DUMAINE, Ph.D.,† RAMON BRUGADA, M.D.,† KUI HONG, M.D.,† URS  
BAUERSFELD, M.D.,‡ FIORENZO GAITA, M.D.,\* and MARTIN BORGGREFE, M.D.


*J Cardiovasc Electrophysiol, Vol. 16, pp. 1-5, January 2005*



# Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG

CHRISTIAN WOLPERT, M.D., RAINER SCHIMPF, M.D., CARLA GIUSTETTO, M.D.,\*  
CHARLES ANTZELEVITCH, Ph.D.,† JONATHAN CORDEIRO, Ph.D.,†  
ROBERT DUMAINE, Ph.D.,† RAMON BRUGADA, M.D.,† KUI HONG, M.D.,† URS  
BAUERSFELD, M.D.,‡ FIORENZO GAITA, M.D.,\* and MARTIN BORGGREFE, M.D.

*J Cardiovasc Electrophysiol, Vol. 16, pp. 1-5, January 2005*



**N588K mutation in  
HERG reduces the  
affinity of the  $I_{Kr}$  channel  
to quinidine by **5.8-fold****


**Quinidine also blocks**

**$I_{Ks}$ ,  $I_{to}$ ,  $I_{K1}$**

# Long-Term Follow-Up of Patients With Short QT Syndrome

Carla Giustetto, MD,\* Rainer Schimpf, MD,† Andrea Mazzanti, MD,\* Chiara Scrocco, MD,\* Philippe Maury, MD,‡ Olli Anttonen, MD,§ Vincent Probst, MD, PhD,|| Jean-Jacques Blanc, MD,# Pascal Sbragia, MD,\*\* Paola Dalmaso, MS,†† Martin Borggrefe, MD,† Fiorenzo Gaita, MD\*


*J. Am. Coll. Cardiol.* 2011;58;587-595




12 pts with Hq  
event Rate 0%/year

35 pts without Hq  
event Rate 4.9%/year

# 72 patients from EuroShort Registry




# 42 ASYMPTOMATIC pts



Patients treated with Hq Log rank p=0.3  
Patients not treated with Hq

# 42 ASYMPTOMATIC pts: 6 occasional finding



occasional finding  
not occasional finding

Log rank  $p=0.5$

**36 yrs, cyclist. No symptoms**


**QT 350 ms**

**QTc 335 ms**






# Stress test:




# SQTS 2

slope  
-1.35



# control group

slope  $-1.30 \pm 0.3$



- no arrhythmias induced at EP study
- KCNQ1 V307L mutation (IKs)

QT 370 ms  
QTc 350 ms



- discharged on Hydroquinidine 250 mg BID

**H.R. 55**



**QT 380 ms**

**QTc 364 ms**


**H.R. 107**



**QT 280 ms**

**QTc 374 ms**

**H.R. 125**



**QT 265 ms**

**QTc 380 ms**

# Short QT Syndrome: How to manage a symptomatic patient with SQTs?

**In patients with aborted cardiac arrest or syncope,  
ICD is presently the first-choice therapy**

# Short QT Syndrome:

How to manage an **asymptomatic** patient with SQTS?

Patients with occasional short QT finding should undergo stress test and 24-hour Holter monitoring to study the QT behavior at different heart rates and genetic testing to better define the diagnosis and, maybe, to guide therapy

# Short QT Syndrome:

## How to manage **asymptomatic** pts?

- As we have not definitive data on predictors of SD yet, ICD should be proposed to adult patients from highly symptomatic families
- Prophylactic treatment with Hydroquinidine should be considered for newborn and children and also for adult patients who refuse ICD implantation

# EUROPEAN REGISTRY ON SHORT QT SYNDROME “EURO-SHORT”

Supported by the European Heart Rhythm  
Association (EHRA)

Correspondence:

Carla Giustetto M.D., Torino, Italy

e-mail [carla.giustetto@unito.it](mailto:carla.giustetto@unito.it)

Rainer Schimpf M.D., Mannheim, Germany

e-mail: [rainer.schimpf@umm.de](mailto:rainer.schimpf@umm.de)